PDCD1 and head and neck squamous cell carcinoma: PD-L1, one of the ligands of PD-1, is upregulated in HNSCC as well as in many types of solid tumors, and in recent studies, it has been shown that patients with high PD-L1 expression achieve better antitumor response and OS in immunotherapy (Patel et al., 2020).